A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In primary ASCVD prevention, the evidence indicates that generic statin-based treatments are cost-effective for people at least down to 1% annual total CVD risk and could be cost-effective at even lower risk,(589) with the highest tolerated statin dose likely the most costeffective.(591,593,594) Importantly, many pati…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.(7,10,11) Cost-effectiveness results strongly depend on parameters such as the target population’s age, the ov…”
BackgroundPicot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., May, M., & Brindle, P. (2007) · BMJ · doi:10.1136/bmj.39261.471806.55 · Cited by 1,038
Clark, A. E., Kaleta, E. J., Arora, A., & Wolk, D. M. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-12 · Cited by 941
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries
Stevens, G., Flaxman, S., Brunskill, E., Mascarenhas, M., Mathers, C. D., & Finucane, M. (2013) · European Journal of Public Health · doi:10.1093/eurpub/ckr176 · Cited by 766
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527
Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis
Dalal, H. M., Zawada, A., Jolly, K., Moxham, T., & Taylor, R. S. (2010) · BMJ · doi:10.1136/bmj.b5631 · Cited by 487
Home-Based Cardiac Rehabilitation
Thomas, R. J., Beatty, A. L., Beckie, T. M., Brewer, L. C., Brown, T. M., Forman, D. E., Franklin, B. A., Keteyian, S. J., Kitzman, D. W., Regensteiner, J. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.008 · Cited by 472
Luqmani, R., Lee, E., Singh, S., Gillett, M., Schmidt, W. A., Bradburn, M., Dasgupta, B., Diamantopoulos, A. P., Forrester-Barker, W., Hamilton, W., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20900 · Cited by 462
Is there evidence that walking groups have health benefits? A systematic review and meta-analysis
Hanson, S., & Jones, A. (2015) · British Journal of Sports Medicine · doi:10.1136/bjsports-2014-094157 · Cited by 452
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
“In addition, we searched the bibliographies of ublished systematic reviews (3,6,7,12–17) and health techology assessments (8,9,18).”
MethodSalami, J. A., Warraich, H., Valero-Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4700 · Cited by 370
Bourne, R. R. A., Jonas, J. B., Bron, A. M., Cicinelli, M. V., Das, A., Flaxman, S. R., Friedman, D. S., Keeffe, J. E., Kempen, J. H., Leasher, J., et al. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311258 · Cited by 349
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Populating an Economic Model with Health State Utility Values: Moving toward Better Practice
Ara, R., & Brazier, J. E. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00700.x · Cited by 334
“EQ-5D equals 1) is used to represent the absence of a health condition, the incremental QALYs gained by an intervention are inflated[2] and the results obtained using a baseline of perfect health are not comparable with those obtained when the baseline is adjusted for not having a particular health condition.[3] There…”
MethodSelf-citationDrug treatment of epilepsy in adults
Schmidt, D., & Schachter, S. C. (2014) · BMJ · doi:10.1136/bmj.g254 · Cited by 323
Synthesising quantitative evidence in systematic reviews of complex health interventions
Higgins, J. P. T., López-López, J. A., Becker, B. J., Davies, S. R., Dawson, S., Grimshaw, J. M., McGuinness, L. A., Moore, T. H. M., Rehfuess, E. A., Thomas, J., et al. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-000858 · Cited by 322
Effectiveness of exercise-referral schemes to promote physical activity in adults: systematic review
Williams, N. H., Hendry, M., France, B., Lewis, R., & Wilkinson, C. (2007) · British Journal of General Practice · doi:10.3399/096016407782604866 · Cited by 321
Lovibond, K., Jowett, S., Barton, P., Caulfield, M., Heneghan, C., Hobbs, F. R., Hodgkinson, J., Mant, J., Martin, U., Williams, B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61184-7 · Cited by 311
Bond, M., Mealing, S., Anderson, R., Elston, J., Weiner, G., Taylor, R., Hoyle, M., Liu, Z., Price, A., & Stein, K. (2009) · Health Technology Assessment · doi:10.3310/hta13440 · Cited by 310
Statins for the primary prevention of cardiovascular disease
Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 305
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
de Lima, R. M. T., dos Reis, A. C., de Menezes, A. P. M., Santos, J. V. D. O., Filho, J. W. G. D. O., Ferreira, J. R. D. O., de Alencar, M. V. O. B., da Mata, A. M. O. F., Khan, I. N., Islam, A., et al. (2018) · Phytotherapy Research · doi:10.1002/ptr.6134 · Cited by 256
Evaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous Meningitis
Nhu, N. T. Q., Heemskerk, D., Thu, D. D. A., Chau, T. T. H., Mai, N. T. H., Nghia, H. D. T., Loc, P. P., Ha, D. T. M., Merson, L., Thinh, T. T. V., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01834-13 · Cited by 244
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Nutescu, E., Chuatrisorn, I., & Hellenbart, E. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0561-1 · Cited by 243
“The ability of antihyperlipidemic agents to reduce the risk of coronary events and stroke have led to a dramatic increase in use over the past decade [67].”
BackgroundThe European cardiac resynchronization therapy survey
Dickstein, K., Bogale, N., Priori, S., Auricchio, A., Cleland, J. G., Gitt, A., Limbourg, T., Linde, C., van Veldhuisen, D. J., Brugada, J., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp359 · Cited by 233
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., & Brindle, P. (2008) · Heart · doi:10.1136/hrt.2007.134890 · Cited by 227
“The statin HTA in the UK has identified a CVD event threshold of 20% in 10 years as the threshold for treatment of which most are non-fatal events.(15)”
BackgroundGustafsson, L. L., Wettermark, B., Godman, B., Andersén‐Karlsson, E., Bergman, U., Hasselström, J., Hensjö, L., Hjemdahl, P., Jägre, I., Julander, M., et al. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00682.x · Cited by 224
Garrett, S., Elley, C. R., Rose, S. B., O'Dea, D., Lawton, B. A., & Dowell, A. C. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x561249 · Cited by 223
Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., et al. (2010) · Blood · doi:10.1182/blood-2010-08-300541 · Cited by 208
Familial hypercholesterolaemia: A model of care for Australasia
Watts, G. F., Sullivan, D. R., Poplawski, N., van Bockxmeer, F., Hamilton-Craig, I., Clifton, P. M., O’Brien, R., Bishop, W., George, P., Barter, P. J., et al. (2011) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2011.06.001 · Cited by 204
“[141] Ward S, Lloyd-Jones M, Pandor A, et al.”
McKinstry, B., Hanley, J., Wild, S., Pagliari, C., Paterson, M., Lewis, S., Sheikh, A., Krishan, A., Stoddart, A., & Padfield, P. (2013) · BMJ · doi:10.1136/bmj.f3030 · Cited by 199
Winkley, K., Upsher, R. J., Stahl, D. R., Pollard, D. J., Kasera, A., Brennan, A., Heller, S. R., & Ismail, K. (2020) · Health Technology Assessment · doi:10.3310/hta24280 · Cited by 197
Arena, R., Williams, M., Forman, D. E., Cahalin, L. P., Coke, L., Myers, J., Hamm, L., Kris-Etherton, P., Humphrey, R., Bittner, V., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318246b1e5 · Cited by 188
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher, M. J., Lazar, L., Bibbins-Domingo, K., Moran, A., Rodondi, N., Coxson, P., Lightwood, J., Williams, L., & Goldman, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00005 · Cited by 187
“A recent systematic review and economic evaluation of statin therapy from the perspective of (and commissioned by) the National Health Service in the United Kingdom (19) estimated cost-effectiveness ratios for primary prevention of $19 380/QALY to $225 600/QALY (at an exchange rate of $2.04 to £1), depending on level…”
BackgroundInfluentialCampbell, F., Holmes, M., Everson-Hock, E., Davis, S., Buckley Woods, H., Anokye, N., Tappenden, P., & Kaltenthaler, E. (2015) · Health Technology Assessment · doi:10.3310/hta19600 · Cited by 185
“TABLE 28 Condition-specific utility values – Ward et al.(68) Condition Utility Healthy 1 CHD initial event 0.”
BackgroundSelf-citationBjelic‐Radisic, V., Cardoso, F., Cameron, D., Brain, E. G. C., Kuljanić, K., da Costa, R. A., Conroy, T., Inwald, E., Serpentini, S., Pinto, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.027 · Cited by 175
Gillett, M., Royle, P., Snaith, A., Scotland, G., Poobalan, A. S., Imamura, M., Black, C., Boroujerdi, M. A., Jick, S. S., Wyness, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16330 · Cited by 175
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Tonelli, M. A., Lloyd, A., Clement, F., Conly, J. M., Husereau, D., Hemmelgarn, B. R., Klarenbach, S. W., McAlister, F. A., Wiebe, N., Manns, B., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.101280 · Cited by 173
Oldridge, N. (2012) · Future Cardiology · doi:10.2217/fca.12.34 · Cited by 171
Mills, E. J., O’Regan, C., Eyawo, O., Wu, P., Mills, F. P., Berwanger, O. B., & Briel, M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr035 · Cited by 164
Westwood, M., van Asselt, T., Ramaekers, B., Whiting, P., Thokala, P., Joore, M., Armstrong, N., Ross, J., Severens, J., & Kleijnen, J. (2015) · Health Technology Assessment · doi:10.3310/hta19440 · Cited by 161
Appropriate perspectives for health care decisions.Preprint
Claxton, K., Palmer, S., Sculpher, M., & Walker, S. (2010) · RePEc: Research Papers in Economics · Cited by 160
Nathavitharana, R. R., Cudahy, P. G. T., Schumacher, S. G., Steingart, K. R., Pai, M., & Denkinger, C. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01075-2016 · Cited by 158
How Patient Centered Are Medical Decisions?: Results of a National Survey
Fowler, F. J., Gerstein, B. S., & Barry, M. J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6172 · Cited by 158
Lipid lowering efficacy of atorvastatin
Adams, S. P., Tsang, M., & Wright, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub2 · Cited by 155
Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome
Bos, L. D. J., Weda, H., Wang, Y., Knobel, H., Nijsen, T. M. E., Vink, T. J., Zwinderman, A. H., Sterk, P. J., & Schultz, M. J. (2014) · European Respiratory Journal · doi:10.1183/09031936.00005614 · Cited by 147
Hoenderboom, B. M., BENTHEM, B. H. B. V., van Bergen, J. E. A. M., Dukers–Muijrers, N. H. T. M., Götz, H. M., Hoebe, C. J. P. A., Hogewoning, A. A., Land, J. A., van der Sande, M. A. B., Morré, S. A., et al. (2019) · Sexually Transmitted Infections · doi:10.1136/sextrans-2018-053778 · Cited by 141
Statin Use Following Intracerebral Hemorrhage: A Decision Analysis
Westover, M. B., Bianchi, M. T., Eckman, M. H., & Greenberg, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.356 · Cited by 136
“Decisionanalyticmodelshave been applied to the clinical issue of anticoagulation in patients with a high risk of falling(8) or a history of ICH,(9) and to the costeffectivenessofstatintherapyincoronaryand cerebrovasculardisease.(1,10,11)Toprovideguidanceforthefrequentlyencounteredquestion ofwhetherstatinuseissafeafter…”
Wasmann, K. A. T. G. M., Wijsman, P. C., van Dieren, S., Bemelman, W. A., & Buskens, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031151 · Cited by 133
A qualitative investigation into patients’ views on visual field testing for glaucoma monitoring
Glen, F. C., Baker, H., & Crabb, D. P. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-003996 · Cited by 130
Greving, J. P., Visseren, F. L. J., de Wit, G. A., & Algra, A. (2011) · BMJ · doi:10.1136/bmj.d1672 · Cited by 128
Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases
Saha, S., Gerdtham, U., & Johansson, P. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7083150 · Cited by 126
“Several models of diabetes and related complications and of CVDs have recently been developed [26,27]; for example, in the fourth Mount Hood Challenge, seven models of diabetes were analyzed [28].”
Robinson, J. G., & Goldberg, A. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.451 · Cited by 123
Conway, V., Couture, P., Richard, C., Gauthier, S., Pouliot, Y., & Lamarche, B. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.03.003 · Cited by 122
Topaz, M., Seger, D. L., Slight, S. P., Goss, F. R., Lai, K. H., Wickner, P. G., Blumenthal, K. G., Dhopeshwarkar, N., CHANG, F. Y., Bates, D. W., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv143 · Cited by 122
Arsenijevic, J., & Groot, W. N. J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012156 · Cited by 120
Akunne, A. F., Murthy, L., & Young, J. B. (2012) · Age and Ageing · doi:10.1093/ageing/afr147 · Cited by 119
Sun, H.-M., Li, X.-Y., Chow, E. P. F., Li, T., Xian, Y., Lu, Y.-H., Tian, T., Zhuang, X., & Zhang, L. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-005997 · Cited by 114
Briggs, A. D. M., Wolstenholme, J. L., Blakely, T. A., & Scarborough, P. (2016) · Population Health Metrics · doi:10.1186/s12963-016-0085-1 · Cited by 113
“for analyzing public health interventions internationally [46], in the Netherlands [47], Switzerland [48], Finland [49, 50], Germany [51], US [52, 53], UK [54, 55], and in Australia [56, 57].”
BackgroundSecular trends and evaluation of complex interventions: the rising tide phenomenon
Chen, Y., Hemming, K., Stevens, A. J., & Lilford, R. J. (2015) · BMJ Quality & Safety · doi:10.1136/bmjqs-2015-004372 · Cited by 112
Roberts, E. T., Horne, A., Martin, S. S., Blaha, M. J., Blankstein, R., Budoff, M. J., Sibley, C. T., Polak, J. F., Frick, K. D., Blumenthal, R. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116377 · Cited by 111
“No statin dose adjustments or tapering of statin efficacy were assumed over the duration of the model [19].”
BackgroundSystematic reviews: from ‘bare bones’ reviews to policy relevance
Snilstveit, B. (2012) · Journal of Development Effectiveness · doi:10.1080/19439342.2012.709875 · Cited by 105
Norman, G., Fayter, D., Lewis-Light, K., Chisholm, J., McHugh, K., Levine, D., Jenney, M. E. M., Mandeville, H., Gatz, S. A., & Phillips, B. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006030 · Cited by 105
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht232 · Cited by 104
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava, A., Kahan, M., & Nader, M. (2017) · PubMed · Cited by 104
Variability Across Ten Production Lots of a Single Demineralized Bone Matrix Product
Bae, H. W., Zhao, L., Zhu, D., Kanim, L. E. A., Wang, J. C., & Delamarter, R. B. (2010) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.h.01400 · Cited by 100
Westwood, M. E., Ramaekers, B. L. T., Grimm, S. E., Worthy, G., Fayter, D., Armstrong, N., Buksnys, T., Ross, J., Joore, M. A., & Kleijnen, J. (2021) · Health Technology Assessment · doi:10.3310/hta25330 · Cited by 97
Monahan, M., Jowett, S., Nickless, A., Franssen, M., Grant, S., Greenfield, S., Hobbs, F. D. R., Hodgkinson, J., Mant, J., & McManus, R. J. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12415 · Cited by 95
“Ten-year cardiovascular risk was calculated for each individual patient, with the distribution of coronary heart disease and stroke events dependent on age and sex.(11,12) Patients who suffered a nonfatal cardiovascular event transitioned to a postevent cardiovascular health state and additional clinical events were n…”
MethodMartin, N. K., Hickman, M., Miners, A. H., Hutchinson, S. J., Taylor, A., & Vickerman, P. T. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003153 · Cited by 95
A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels
Carswell, K. A., Belgaumkar, A. P., Amiel, S. A., & Patel, A. G. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1829-x · Cited by 94
Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey
Park, J. E., Chiang, C., Munawar, M., Pham, G. K., Sukonthasarn, A., Aquino, A. R., Lin, K. K., & Chan, H. W. R. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826710397100 · Cited by 94
Becerra, V., Gracia, A., Desai, K., Abògúnr̀in, Ṣ., Brand, S. B., Chapman, R., Alonso, F. G., Fuster, V., & Sanz, G. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-007111 · Cited by 93
Bocșan, I. C., Măgureanu, D. C., Pop, R. M., Levai, A. M., Macovei, Ș. O., Pătrașca, I. M., Chedea, V. S., & Buzoianu, A. D. (2022) · Biomedicines · doi:10.3390/biomedicines10102337 · Cited by 92
Ose, L., Budinski, D., Hounslow, N. J., & Arneson, V. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903290886 · Cited by 90
Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes
Armenian, S. H., Landier, W., Hudson, M. M., Robison, L. L., & Bhatia, R. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24422 · Cited by 90
Virk, M. S., Alaee, F., Tang, H., Ominsky, M. S., Ke, H. Z., & Lieberman, J. R. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.00285 · Cited by 84
Scholes, S., Biddulph, J. P., Davis, A. C., & Mindell, J. S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019615 · Cited by 83
Rosuvastatin for lowering lipids
Adams, S. P., Sekhon, S. S., & Wright, J. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010254.pub2 · Cited by 83
Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis
Biffi, A., Devan, W. J., Anderson, C. D., Ayres, A. M., Schwab, K. M., Cortellini, L., Viswanathan, A., Rost, N. S., Smith, E. E., Goldstein, J. N., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182194be9 · Cited by 82
Ademi, Z., Watts, G. F., Juniper, A., & Liew, D. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.280 · Cited by 80
Impact of Physician–Patient Discussions on Patient Satisfaction
Chen, J. Y., Tao, M. L., Tisnado, D. M., Malin, J. L., Ko, C. Y., Timmer, M., Adams, J., Ganz, P. A., & Kahn, K. L. (2008) · Medical Care · doi:10.1097/mlr.0b013e31817924bc · Cited by 79
Systematic Review of Chinese Traditional Exercise Baduanjin Modulating the Blood Lipid Metabolism
Mei, L., Chen, Q., Ge, L., Zheng, G., & Chen, J. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/282131 · Cited by 79
“The study found that the effective management of hyperlipidemia could obviously reduce cardiovascular morbidity and mortality substantially [5].”
BackgroundMickenautsch, S., & Yengopal, V. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146512 · Cited by 79
“the number of failures out of 100, for both test- and control intervention was generated with help of the Visual Rx—Statin Calculator by Cates [23,24].”
MethodWaugh, N., Black, C., Walker, S., McIntyre, L., Cummins, E., & Hillis, G. S. (2006) · Health Technology Assessment · doi:10.3310/hta10390 · Cited by 79
Controversies in ocular tuberculosis
Ang, M., & Chee, S.-P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309531 · Cited by 78
NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models
Ara, R., & Wailoo, A. (2011) · Europe PMC (PubMed Central) · Cited by 78
Self-citation
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.